替格瑞洛用于高龄患者经皮冠状动脉介入术后抗血小板治疗的疗效与安全性  

Efficacy and Safety of Ticagrelor in Postoperative Antiplatelet Therapy in Elderly Patients with Percutaneous Coronary Intervention

作　　者：曾文峰[1] 蔡楠 刘敬峰 ZENG Wenfeng;CAI Nan;LIU Jingfeng(Dept. of Cardiovascular Medicine, Meizhou People’s Hospital, Guangdong Meizhou 514000, China)

机构地区：[1]梅州市人民医院心血管内一科,广东梅州514000

出　　处：《中国医院用药评价与分析》2020年第3期312-314,318,共4页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:探讨替格瑞洛用于高龄患者经皮冠状动脉介入术(percutaneous coronary intervention,PCI)后抗血小板治疗的疗效与安全性。方法:回顾性选取2017年1月至2018年6月梅州市人民医院收治的202例行PCI术高龄患者的临床资料,将其中以阿司匹林联合替格瑞洛治疗的88例纳入研究组,以阿司匹林联合氯吡格雷治疗的114例纳入对照组。比较两组患者的临床疗效、治疗前后的全血C反应蛋白(CRP)水平、不良反应发生情况及治疗后6个月主要不良心血管事件发生情况的差异。结果:研究组患者的总有效率为97.73%(86/88),明显高于对照组的83.33%(95/114),差异有统计学意义(P<0.05)。治疗后,研究组患者全血CRP水平明显低于对照组,差异有统计学意义(P<0.05)。两组患者心律失常、呼吸困难、胃肠道不适及皮肤瘙痒等不良反应发生率的差异均无统计学意义(P>0.05)。治疗后6个月,研究组患者支架内血栓形成的发生率明显低于对照组,差异有统计学意义(P<0.05);两组患者心肌梗死发生率、心绞痛发生率及死亡率的差异均无统计学意义(P>0.05)。结论:替格瑞洛用于高龄患者PCI术后抗血小板治疗的疗效显著,有利于减轻炎症反应,不会增加不良反应,且预后较佳。OBJECTIVE:To probe into the efficacy and safety of ticagrelor in postoperative antiplatelet therapy in elderly patients with percutaneous coronary intervention(PCI).METHODS:Clinical data of 202 elderly patients with PCI admitted into Meizhou People’s Hospital from Jan.2017 to Jun.2018 were retrospectively extracted.A total of 88 patients treated with aspirin combined with tigrillo were enrolled in the study group and 114 patients treated with clopidogrel were enrolled in the control group.The clinical efficacy,levels of blood C-reactive protein(CRP)before and after treatment,incidence of adverse drug reactions,and major adverse cardiovascular events after treatment of 6 months of two groups were compared.RESULTS:The total effective rate of the study group was 97.73%(86/88),significantly higher than that of the control group[83.33%(95/114)],and the difference was statistically significant(P<0.05).After treatment,the levels of CRP in the study group was significantly lower than that in the control group,and the difference was statistically significant(P<0.05).There were no significant differences in the incidence of arrhythmia,dyspnea,gastrointestinal upset and skin itching between two groups(P>0.05).After treatment of 6 months,the incidence of stent thrombosis in the study group was significantly lower than that in the control group,with statistically significant differences(P<0.05),while there was no statistically significant difference in the incidence and mortality of myocardial infarction and angina pectoris between two groups(P>0.05).CONCLUSIONS:The efficacy of ticagrelor in postoperative antiplatelet therapy in elderly patients with PCI is significant,which is conducive to reducing the inflammatory response,without increasing the incidence of of adverse drug reactions,and has better prognosis.

关 键 词：经皮冠状动脉介入术 主要不良心血管事件 替格瑞洛 抗血小板治疗 安全性 

分 类 号：R972[医药卫生—药品]